Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience.
Hereditary angioedema
Lanadelumab
Prophylaxis
Real-life
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
02
02
2022
revised:
04
05
2022
accepted:
05
06
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
To explore and compare the efficacy of standard (300 mg every 2 weeks) and extended (300 mg every 4 weeks) dosing regimens of lanadelumab for long-term prophylaxis of hereditary angioedema (HAE). We conducted a retrospective chart review of all patients with HAE on lanadelumab, which identified a total of 9 patients: 5 females and 4 males. The median age of patients was 31 years (IQR 20.7). The mean number of attacks per month before starting lanadelumab was 5.9 (SD 6.3). Patients were started on 300 mg of lanadelumab subcutaneously, every 2 weeks (standard group, n = 5) or every 4 weeks (extended group, n = 4). We observed a statistically significant improvement in the number of angioedema attacks per month in all 9 patients ( Lanadelumab is a safe and effective agent for long-term prophylaxis of HAE. An extended dosing regimen was equally effective as prophylaxis compared to a standard regimen. Further studies are needed to compare the 2 regimens in a larger patient group.
Identifiants
pubmed: 35891672
doi: 10.1016/j.waojou.2022.100664
pii: S1939-4551(22)00040-0
pmc: PMC9287634
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100664Informations de copyright
© 2022 The Author(s).
Références
J Allergy Clin Immunol Pract. 2021 Oct;9(10):3744-3751
pubmed: 34023564
Case Reports Immunol. 2018 Oct 29;2018:7435870
pubmed: 30510820
JAMA. 2018 Nov 27;320(20):2108-2121
pubmed: 30480729
Ann Allergy Asthma Immunol. 2015 Apr;114(4):281-288.e7
pubmed: 25707325
Allergy. 2014 May;69(5):602-16
pubmed: 24673465
Allergy. 2018 Aug;73(8):1575-1596
pubmed: 29318628
World Allergy Organ J. 2022 Apr 07;15(3):100627
pubmed: 35497649
J Drugs Dermatol. 2020 Oct 1;19(10):978-983
pubmed: 33026762
Allergy Asthma Clin Immunol. 2021 Jul 23;17(1):78
pubmed: 34301329